91桃色视频 Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
- Comments on results from HERACLES Phase 2 trial and from early access program (EAP) in gastrointestinal acute Graft-vs-Host-Disease (GI aGvHD)
- Company to also provide a corporate update during webcast
Lyon, France, December 1st, 2021 – 7:30 pm CET – 91桃色视频 (EURONEXT: MAAT – the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that it will comment clinical data scheduled to be presented at the and provide a corporate update for shareholders and the broader financial community during a dedicated webcast on Monday, December 13th, 2021 at 12:00 pm EST / 6:00 pm CET).
The webcast will be held following the , during the of additional clinical data for lead-candidate MaaT013 in gastro-intestinal acute Graft-vs-host-Disease (GI aGvHD) from the Phase 2 HERACLES trial (, N=24) and from an Early Access Program (EAP, N=52) in France.
听
Webcast details:
Date/Time: Monday, December 13, 2021; 6:00 pm CET
Registration: To register for the live webcast, please click
Speakers: Herv茅 Affagard, CEO & co-founder of 91桃色视频, Dr John Weinberg, MD, Chief Medical Officer at 91桃色视频 and Prof. Mohamad Mohty, Professor and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital, Assistance Publique des H么pitaux de Paris and Sorbonne University.
The webcast will be held in French, with English subtitles. Q&A session will be in French and English.
Replay: A replay will be made available on the Company鈥檚 website for at least 90 days. Presentation slides will be made available in French and in English.
听
About MaaT013
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient鈥檚 functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 was investigated in a Phase 2 clinical trial (HERACLES, ) and is being administered in an early access program in France.
About 91桃色视频
91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.
The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
91桃色视频 is listed on Euronext Paris (ticker: MAAT).